Effects of pulmonary rehabilitation on lung function in chronic obstructive pulmonary disease: The FIRST study.

European Journal of Physical and Rehabilitation Medicine

Volumn 50, Issue 4, 2014, Pages 419-426

  Incorvaia, C ^a   Russo, A ^b   Foresi, A ^a   Berra, D ^c   Elia, R ^a   Passalacqua, G ^d   Riario Sforza, G G ^a   Ridolo, E ^e  

^a PARKINSON INSTITUTE   (Italy)

^b Local Health Authority   (Italy)

^c OSPEDALE DI CIRCOLO   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF PARMA   (Italy)

Author keywords

Chronic obstructive; Pulmonary disease; Rehabilitation; Respiration

Indexed keywords

AGED; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; KINESIOTHERAPY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; EXERCISE THERAPY; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84920953032     PISSN: 19739087     EISSN: 19739095     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Global Initiative for Chronic Obstructive Pulmonary Disease Global Strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Bethesda, MD National Heart, Lung and Blood Institute; April 2001 (updated 2007).
2. Fletcher C, Peto R. The natural history of chronic airflow obstruction, Br Med J 1977; 1: 1645-48.
3. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-53
4. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Laslen TK. Randomised, double blind placebo controlled study of fluticasone priopionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303.
5. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000: 343: 1902-9
6. Soriano JB, Sin DD, Zhang X, Camp PG, Anderson JA, Anthonisen NR, Buist AS et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007; 131: 682-9.
7. Vestbo J, Ewards LD, Scanlon PD, Yates JC, Agusti A, Bakke P et al. Changes in forces expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184-92.
8. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994; 272: 1497-505.
9. Scanlon PD, Connett JE, Waller LA, Altose MD, Bayley WC, Buist AS, for the Lung Health Study Research Group. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381-90.
10. Celli BR, Thomas NE. Anderson JA, Ferguson GT, Jenkins CR, Jones PW et al. Effects of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease Results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-8.
11. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54.
12. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173: 1390-413.
13. Ries AL, Bauldoff GF, Carlin BV, Casaburi R, Emery CF, Mahler DA et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007; 131 (Suppl. 5): 4-42.
14. Cote CG, Celli BR. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005; 26: 630-6.
15. Foglio K, Bianchi L, Bruletti G, Porta R, Vitacca M, Balbi B et al. Seven-year time course of lung function, symptoms, health-related quality of life, and exercise tolerance in COPD patients undergoing pulmonary rehabilitation programs. Resp Med 2007; 101: 1961-70.
16. Stav D, Raz M, Shpirer I. Three years of pulmonary rehabilitation inhibit the decline in airflow obstruction, improves exercise endurance time, and body-mass index, in chronic obstructive pulmonary disease. BMC Pulm Med 2009; 9: 26-30.
17. Brusasco V, Crapo R, Viegi G; American Thoracic Society; European Respiratory Society. Coming together: the ATS/ERS consensus on clinical pulmonary function testing. Eur Respir J 2005; 26: 1-2.
18. Riario-Sforza GG, Incorvaia C, Paterniti F, Pessina L, Caligiuri R, Pravettoni C et al. Effects of pulmonary rehabilitation on exercise capacity in patients with COPD: a number needed to treat study. Int J Chron Obstruct Pulmon Dis 2009; 4: 315-9.
19. Chen YJ, Macera CA, Addy CL, Sy FS, Wieland D, Blair SN. Effects of physical activity on exercise tests and respiratory function. Br J Sports Med 2003; 37: 521.8.
20. Pelkonen M, Notkola IL, Lakka T, Tukianen HO, Kivinen P, Nissinen A. Delaying decline in pulmonary function with physical activity: a 25-year follow-up. Am J Respir Crit Care Med 2003; 168: 494-9.
21. Garcia-Aymerich J, Lange P, Benet M, Schnor P, Antò JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 458-63.
22. Redelmeyer DA, Bayoumi A, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155: 1278-82.
23. Riario-Sforza GG, Incorvaia C. Change in FEV1 over time in COPD. N Engl J Med 2011; 365: 2540; author reply 2541.
24. Clark N, Jones P, Keller S, Vermeire P. Patient factors and compliance with asthma therapy. Respir Med 1999; 93: 856-62
25. Incorvaia C, Riario-Sforza GG. Effect of patient education on adherence to drug treatment for chronic obstructive pulmonary disease. Ann Thorac Med 2011; 6: 242-3.
26. Vogelmeier Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-103
27. Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A et al. Effect of fluticasone propionate/salmeterol (250/50 microg) on COPD exacerbations and impact on patient outcomes. COPD 2009; 6: 320-9.
28. Johnston K, Grimmer-Somers K. Pulmonary rehabilitation: overwhelming evidence but lost in translation? Physiother Can 2010; 62: 368-73.